At the annual general meeting of STRATEC Biomedical AG held on June 14, 2017, the company's shareholders approved the distribution of a dividend of EUR 0.77 per share for the 2016 financial year (previous year: EUR 0.75 per share). The distribution total amounts to EUR 9.1 million and will be paid out to shareholders via their depositing banks on June 20, 2017.

Shareholders approved the actions of the Board of Management and the Supervisory Board and elected Roland Baule (68), Managing Director of Baule GmbH and former CEO of Fresenius Kabi AG, to the Supervisory Board. He will succeed Wolfgang Wehmeyer, who retired from the Supervisory Board at his own request upon the conclusion of the Annual General Meeting. STRATEC's Board of Management and Supervisory Board would like to take this opportunity to thank Mr. Wehmeyer for the good and close working relationship over the years.